Novel bronchodilators for the treatment of chronic obstructive pulmonary disease

Trends in Pharmacological Sciences

Volumn 32, Issue 8, 2011, Pages 495-506

  Matera, Maria Gabriella ^a   Page, Clive P ^b   Cazzola, Mario ^c,d  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; AZD 3199; BEA 2180BR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHF 5407; CORTICOSTEROID; DEXPIRRONIUM; DOXOFYLLINE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GS 424020; GSK 573719; GSK 961081; INDACATEROL; IPRATROPIUM BROMIDE; LAS 100977; LAS 40464; MFF 258; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PF 4522971; PF 610355; QMF 149; QVA 149; RBX 343E 48F 0; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; DISEASE COURSE; DRUG APPROVAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SALVAGE THERAPY; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, MUSCARINIC;

EID: 79960958698     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.04.003     Document Type: Review

References (67)

1. K.F. Rabe Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am. J. Respir. Crit. Care Med. 176 2007 532 555 (Pubitemid 47403272)
2. M. Cazzola, and M.G. Matera Novel long-acting bronchodilators for COPD and asthma Br. J. Pharmacol. 155 2008 291 299
3. M. Cazzola, and M.G. Matera Emerging inhaled bronchodilators: an update Eur. Respir. J. 34 2009 757 769
4. E.L. Toy Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs Respir. Med. 105 2011 435 441
5. 2- agonist, on isolated human bronchi Eur. Respir. J. 29 2007 575 581 (Pubitemid 46372108)
6. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices J. Pharmacol. Exp. Ther. 324 2008 70 75
7. 2 adrenoceptor agonist with a 24-h duration of action J. Pharmacol. Exp. Ther. 317 2006 762 770
8. M. Cazzola Indacaterol for chronic obstructive pulmonary disease (COPD) Drugs Today (Barc.) 46 2010 139 150
9. 2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
10. 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models J. Pharmacol. Exp. Ther. 334 2010 53 62
11. 2 agonist: investigations to understand its long duration of action [abstract] Am. J. Respir. Crit. Care Med. 179 2009 A1919
12. 2 agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A4443
13. 2-agonist, is effective in COPD patients [abstract] Am. J. Respir. Crit. Care Med. 179 2009 A6183
14. 1/2/3 adrenoceptor cAMP assays [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A4451
15. 2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A4453
16. 2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A4447
17. N. Hanania Dose-related efficacy of vilanterol trifenatate in COPD [abstract] Eur. Respir. J. 36 2010 217 s
18. M. Aparici The in vitro pharmacological profile of LAS100977 - a potent, selective and long-acting beta-2 receptor agonist [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A5675
19. 2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup J. Med. Chem. 53 2010 6640 6652
20. 2 adrenoreceptor agonist, PF-00610355 in asthmatic patients [abstract] Eur. Respir. J. 34 2009 778 s
21. P. Norman Which of three structures is AZD-3199?. WO-2008104790 WO-2008096112 and WO-2008096119 Expert Opin. Ther. Pat. 19 2009 1157 1163
22. 1 response to an inhaled long-acting anti-muscarinic in COPD patients J. Pharmacokinet. Pharmacodyn. 38 2011 105 119
23. P. Casarosa Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs J. Pharmacol. Exp. Ther. 330 2009 660 668
24. G. Villetti Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways Br. J. Pharmacol. 148 2006 291 298 (Pubitemid 43801176)
25. C. Verkindre Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Respir. Med. 104 2010 1482 1489
26. C. Vogelmeier Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients Pulm. Pharmacol. Ther. 23 2010 438 444
27. A. Gavald Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J. Pharmacol. Exp. Ther. 331 2009 740 751
28. M. Cazzola Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD Curr. Opin. Investig. Drugs 10 2009 482 490
29. S. Sentellas Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites Eur. J. Pharm. Sci. 39 2010 283 290
30. G. Joos Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients Respir. Med. 104 2010 865 872
31. H. Magnussen Efficacy and safety of aclidinium bromide 400 μg BID compared with placebo and tiotropium in patients with moderate to severe COPD [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A4440
32. P.W. Jones Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [abstract] Am. J. Respir. Crit. Care Med. 183 2011 A6350
33. 3 receptor antagonist J. Pharmacol. Exp. Ther. 335 2010 622 635
34. L. Oleson ALKS 27 (trospium inhalation powder) improves lung function following single administration in subjects with COPD [abstract] Am. J. Respir. Crit. Care Med. 181 2010 A4457
35. 3 antagonist [abstract] Eur. Respir. J. 36 2010 219 s
36. S. Gupta Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: a novel, long acting muscarinic receptor antagonist Eur. J. Pharmacol. 658 2011 219 228
37. 2 agonists and theophylline in stable chronic obstructive pulmonary disease Thorax 54 1999 730 736 (Pubitemid 29341411)
38. R.L. ZuWallack Salmeterol plus theophylline combination therapy in the treatment of COPD Chest 119 2001 1661 1670
39. P.A. Ford Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD Chest 137 2010 1338 1344
40. C.P. Page Doxofylline: a novofylline Pulm. Pharmacol. Ther. 23 2010 231 234
41. V. Boswell-Smith Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. 117 2006 1237 1243 (Pubitemid 43795733)
42. P.M.A. Calverley Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials Lancet 374 2009 684 695
43. 1 Chest 129 2006 5 6 (Pubitemid 43273177)
44. 4-induced contractions in passively sensitized human airways Br. J. Pharmacol. 131 2000 1607 1618 (Pubitemid 32056426)
45. C.K. Billington A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells Am. J. Respir. Cell Mol. Biol. 38 2008 1 7
46. D. Singh The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma Respir. Res. 11 2010 26
47. S. Danto A randomized, double-blind, placebo-controlled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD [abstract] Am. J. Respir. Crit. Care Med. 175 2007 A131
48. H.J. Gutke AWD-12-281 (inhaled) (elbion/GlaxoSmithKline) Curr. Opin. Investig. Drugs 6 2005 1149 1158
49. J. Vestbo A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Eur. Respir. J. 33 2009 1039 1044
50. K.H. Banner, and N.J. Press Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease Br. J. Pharmacol. 157 2009 892 906
51. M. Cazzola, and D.P. Tashkin Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function COPD 6 2009 404 415
52. J.A. van Noord QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease Thorax 65 2010 1086 1091
53. F. Maltais Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract] Eur. Respir. J. 36 2010 1014 s
54. 2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner Mol. Pharmacol. 79 2011 389 399
55. L.M. Fabbri Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomized clinical trials Lancet 374 2009 695 703
56. I. Peretto Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists Med. Res. Rev. 29 2010 867 902
57. J. Lötvall Safety and efficacy of fluticasone furoate/vilanterol trifenatate in COPD patients [abstract] Eur. Respir. J. 36 2010 1013 s
58. E.G. Barrett A novel mutual prodrug of salmeterol and desisobutrylciclesonide attenuates acute bronchoconstriction in the absence of cardiovascular side-effects in ragweed sensitized and naïve dogs Am. J. Respir. Crit. Care Med. 181 2010 A4249
59. P.J. Barnes New therapies for chronic obstructive pulmonary disease Med. Princ. Pract. 19 2010 330 338
60. D. Wu Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review Respir. Res. 12 2011 45
61. L.B. Fernandes Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease Ther. Adv. Respir. Dis. 1 2007 25 33
62. R. Gosens Role of Rho-kinase in maintaining airway smooth muscle contractile phenotype Eur. J. Pharmacol. 483 2004 71 78 (Pubitemid 38056606)
63. A.M. Hamad Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle Am. J. Physiol. 273 1997 L807 L813
64. A.M. Hamad Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function Am. J. Physiol. Lung Cell. Mol. Physiol. 285 2003 L973 L983
65. M.G. Matera Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi Pulm. Pharmacol. Ther. 22 2009 478 482
66. M.G. Matera Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi Br. J. Pharmacol. 2011 10.1111/j.1476-5381.2011.01339.x
67. R. Kessler Symptom variability in patients with severe COPD: a pan-European cross-sectional study Eur. Respir. J. 37 2011 264 272